Dovato (dolutegravir and lamivudine)

Dovato is a novel pharmaceutical used to treat HIV-I in adults and was approved in April of 2019. Dovato is a combination drug that includes two previously approved drug, dolutegravir, approved for the treatment of HIV-I in 2013, and lamivudine, approved for the treatment of HIV/AIDS in 1995. Dolutegravir is an integrase strand transfer inhibitor (INSTI), which stops the replication of HIV by blocking viral DNA from integrating into the genetic material of T-cells. Lamivudine is a nucleoside analogue reverse transcriptase inhibitor (NRTI), which, when phosphorylated, forms active metabolites that compete for incorporation into viral DNA. If incorporated into DNA, lamivudine metabolites competitively inhibit the activity of HIV reverse transcriptase and act as a chain terminator of DNA synthesis. In other words, it works by interfering with the conversion of viral RNA into DNA. The combination of dolutegravir and lamivudine into a single drug, Dovato, allows for the inclusion of two different classes of HIV-treating drugs in a single dose of medication, while preventing a patient from having to take more that one pill. Furthermore, there are some combination drugs already approved which include both dolutegravir and lamivudine in them but they also include other drugs as well. For example, Triumeq is a combination drug used to treat HIV, which includes both dolutegravir and lamivudine as well as Abacavir, which is another Nucleoside Reverse Transcriptase Inhibitors. In essence, Dovato offers another combination drug option without some of the redundancy seen in other combination drugs that include more than one drug of a specific class. This may prove useful in treatment during the earlier stages of HIV, when one’s immune system is still fairly strong and starting out with fewer drugs may be beneficial in minimizing side effects while still receiving adequate coverage and treatment

Leave a comment

Privacy Statement